Literature DB >> 7610837

Squamous cell carcinoma is highly sensitive to taxol, a possible new radiation sensitizer.

L Elomaa1, H Joensuu, J Kulmala, P Klemi, R Grénman.   

Abstract

We studied the sensitivity of seven cell lines established from laryngeal carcinoma to the cytotoxic drug paclitaxel (Taxol) in vitro. In all four cell lines tested for growth inhibition, paclitaxel reduced growth at low concentrations, and in two cell lines growth was completely inhibited at a paclitaxel concentration of only 1 x 10(-8) M. Flow cytometric data showed a G2/M block in all seven cell lines after exposure to paclitaxel for 24 h at a concentration of 1 x 10(-8) M. This concentration is about one-one hundredth fold smaller than those measured in serum after a single intravenous dose of about 200 mg/m2. The high in vitro sensitivity of laryngeal cancer cell lines to paclitaxel,and the G2/M block suggest that the drug may potentially be used in conjunction with radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7610837     DOI: 10.3109/00016489509139325

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  8 in total

1.  Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study.

Authors:  Amal Ahmed-Fouad Halim; Hanan Ahmed Wahba; Hend Ahmed El-Hadaad; Ahmed Abo-Elyazeed
Journal:  Med Oncol       Date:  2011-01-30       Impact factor: 3.064

2.  [Preoperative radiochemotherapy of advanced resectable cancer of the oral cavity with cisplatin vs paclitaxel/carboplatin. Analysis of two multimodality treatment concepts].

Authors:  A Eckardt; G Wegener; J H Karstens
Journal:  Mund Kiefer Gesichtschir       Date:  2006-01

3.  [Simultaneous radiochemotherapy with taxol/carboplatin in advanced operable head-neck tumors. Preliminary results].

Authors:  A Eckardt; I Wildfang; J H Karstens
Journal:  Strahlenther Onkol       Date:  1999-10       Impact factor: 3.621

4.  Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.

Authors:  Ananth K Vellimana; Violette Renard Recinos; Lee Hwang; Kirk D Fowers; Khan W Li; Yonggang Zhang; Saint Okonma; Charles G Eberhart; Henry Brem; Betty M Tyler
Journal:  J Neurooncol       Date:  2012-12-07       Impact factor: 4.130

5.  Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer.

Authors:  J O Pulkkinen; L Elomaa; H Joensuu; P Martikainen; K Servomaa; R Grenman
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

6.  Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck.

Authors:  Ammar Sukari; Marwan Al-Hajeili; Mohamed Salem; Lance Heilbrun; Daryn Smith; George Yoo; John R Jacobs; Ho-Sheng Lin; Omer Kucuk
Journal:  Avicenna J Med       Date:  2015 Apr-Jun

7.  A new core-shell-type nanoparticle loaded with paclitaxel/norcantharidin and modified with APRPG enhances anti-tumor effects in hepatocellular carcinoma.

Authors:  Ming-Hua Xie; Zai-Lin Fu; Ai-Lian Hua; Ji-Fang Zhou; Qian Chen; Jian-Bo Li; Shen Yao; Xin-Jun Cai; Min Ge; Li Zhou; Jia Wu
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

8.  Genotyping and Characterization of HPV Status, Hypoxia, and Radiosensitivity in 22 Head and Neck Cancer Cell Lines.

Authors:  Eva-Leonne Göttgens; Marleen Ansems; William P J Leenders; Johan Bussink; Paul N Span
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.